E
SF Streetcar at Pine St

JPM17 Healthcare Conference Day 3 Highlights

Commentary on Wednesday at JPM17 in San Francisco

January 11, 2017
E

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017
E

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016
E

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016
E

New developments in allogeneic cellular therapies

Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?

August 5, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
E

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
E

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015
E

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015
E
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015
E

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
E

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015
E

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015
E

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E

The Potential of Gene Therapy to Restore Hearing Loss

Restoration of hearing in mice by gene transfer is a major breakthrough

August 14, 2012